quinazolines has been researched along with Muscular Atrophy, Spinal in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Erdem, SS; Sabuncu Gürses, G; Saçan, MT | 1 |
| Butchbach, MER; Connell, AJ; Gentillon, C; Kirk, RW | 1 |
| Androphy, EJ; Calo, A; Cherry, JJ; Custer, SK; DiDonato, CJ; Du, S; Foley, TL; Gopalsamy, A; Gordo, SM; Gordon, W; Hosea, N; Jones, LH; Krizay, DK; LaRosa, G; Li, H; Mathur, S; Menard, CA; Patel, P; Potter, K; Ramos-Zayas, R; Reedich, EJ; Rietz, A; Rong, H; Tones, MA; Zhang, B | 1 |
| Akashi, K; Al-Raqad, M; Arai, F; Bauer, DE; Buonamici, S; Canver, MC; Cole, MA; Ishikawa, Y; Macias-Trevino, C; Maeda, M; Maeda, T; Masuda, T; Nakano, M; Orkin, SH; Pinello, L; Reversade, B; Schoonenberg, VAC; Seiler, M; Semba, Y; Shboul, M; Yamauchi, T; Yao, Q | 1 |
| Feng, Z; Gibbs, RM; Jacques, V; Ko, CP; Li, DK; Lin, MY; Miao, W; Pellizzoni, L; Plasterer, HL; Rucki, AA; Rusche, JR; Sharma, S; Sumner, CJ; Van Meerbeke, JP; Wee, CD; Xia, B | 1 |
| Bail, S; Barlow, C; Cardona, H; DiDonato, CJ; Durens, M; Emery, C; Gogliotti, RG; Heier, CR; Jacques, V; Jarecki, J; Jorgensen, M; Kiledjian, M; Kuntz, N; Plasterer, HL; Rusche, J; Singh, J; Xia, B | 1 |
| Burghes, AH; Butchbach, ME; Gurney, ME; Singh, J | 1 |
| Butchbach, ME; Harris, AW | 1 |
| Cherry, JJ; Fadeyi, O; Foley, TL; Gopalsamy, A; Jones, LH; Kyne, RE; LaRosa, G; Liu, S; Loria, PM; Maglich-Goodwin, J; Menard, C; Nabhan, JF; Narayanan, A; Noell, S; Parikh, MD; Petersen, DN; Ren, Y; Rong, H; Tones, MA | 1 |
| Bjornsson, JM; Christensen, J; Gurney, ME; Jarecki, J; Kiledjian, M; Liu, SW; Mattoon, DR; Michaud, G; Mishra, R; Pollok, BA; Printen, J; Salcius, M; Singh, J; Staker, BL; Stewart, L; Thurmond, J | 1 |
| Andrésson, T; Burghes, AH; Butchbach, ME; Edwards, JD; Gurney, ME; Jarecki, J; Pellizzoni, L; Saieva, L; Simard, LR; Singh, J; Slominski, E; Thorsteinsdóttir, M; Thurmond, J; Zhang, J | 1 |
| Andresson, T; Bedell, L; Bjornsson, JM; Bragason, G; Burghes, AH; Butchbach, ME; Coovert, DD; Gurney, ME; Haraldsson, M; Keyvan, M; Mishra, R; Pai, G; Palomo, M; Pease, B; Rao, M; Singh, J; Thosteinsdottir, M; Thurmond, J | 1 |
12 other study(ies) available for quinazolines and Muscular Atrophy, Spinal
| Article | Year |
|---|---|
A QSAR study to predict the survival motor neuron promoter activity of candidate diaminoquinazoline derivatives for the potential treatment of spinal muscular atrophy.
Topics: Humans; Motor Neurons; Muscular Atrophy, Spinal; Quantitative Structure-Activity Relationship; Quinazolines | 2023 |
The effects of C5-substituted 2,4-diaminoquinazolines on selected transcript expression in spinal muscular atrophy cells.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Cells, Cultured; Humans; Mice; Muscular Atrophy, Spinal; Quinazolines; RNA, Messenger; Survival of Motor Neuron 2 Protein; Transcription, Genetic | 2017 |
In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels.
Topics: Animals; Cell Line; Disease Models, Animal; Endoribonucleases; Enzyme Inhibitors; Female; Gene Knockdown Techniques; HEK293 Cells; Humans; Male; Mice; Mice, Knockout; Muscular Atrophy, Spinal; Promoter Regions, Genetic; Quinazolines; RNA, Messenger; Survival of Motor Neuron 2 Protein | 2017 |
Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.
Topics: Animals; Cell Line; CRISPR-Cas Systems; Endoribonucleases; Humans; Leukemia; Male; Metabolic Networks and Pathways; Mice, Inbred C57BL; Muscular Atrophy, Spinal; Quinazolines; RNA Precursors; RNA Splicing; RNA, Messenger | 2018 |
The DcpS inhibitor RG3039 improves motor function in SMA mice.
Topics: Animals; Central Nervous System; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endoribonucleases; Humans; Mice; Mice, Transgenic; Motor Neurons; Muscles; Muscular Atrophy, Spinal; Neuromuscular Junction; Quinazolines; Ribonucleoproteins, Small Nuclear; Survival of Motor Neuron 1 Protein; Survival of Motor Neuron 2 Protein; Synaptic Transmission | 2013 |
The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endoribonucleases; Female; Humans; Mice; Mice, Transgenic; Motor Neurons; Muscular Atrophy, Spinal; Quinazolines; Survival of Motor Neuron 2 Protein; Synapses | 2013 |
The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice.
Topics: Animals; Brain; Diet; Disease Models, Animal; Female; Male; Mice; Muscular Atrophy, Spinal; Pregnancy; Prenatal Exposure Delayed Effects; Quinazolines; Severity of Illness Index; SMN Complex Proteins; Spinal Cord; Treatment Outcome | 2014 |
The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy.
Topics: Animals; Body Weight; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Endoribonucleases; Female; Follistatin; Kaplan-Meier Estimate; Male; Mice; Mice, Transgenic; Motor Activity; Muscular Atrophy, Spinal; Quinazolines; Recombinant Proteins; Survival of Motor Neuron 1 Protein; Survival of Motor Neuron 2 Protein | 2015 |
Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA).
Topics: Animals; Disease Models, Animal; Drug Design; Endoribonucleases; Enzyme Inhibitors; HEK293 Cells; Humans; Mice; Molecular Docking Simulation; Muscular Atrophy, Spinal; Quinazolines; RNA, Messenger; Survival of Motor Neuron 2 Protein | 2017 |
DcpS as a therapeutic target for spinal muscular atrophy.
Topics: Drug Delivery Systems; Endoribonucleases; Humans; Muscular Atrophy, Spinal; Protein Binding; Protein Conformation; Quinazolines | 2008 |
Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy.
Topics: Animals; Cell Survival; Disease Models, Animal; Gene Expression; Humans; Mice; Mice, Knockout; Mice, Transgenic; Motor Neurons; Muscular Atrophy, Spinal; Phenotype; Promoter Regions, Genetic; Quinazolines; Survival of Motor Neuron 2 Protein | 2010 |
Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
Topics: Aminoquinolines; Animals; Biological Availability; Blood-Brain Barrier; Cell Line; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Fibroblasts; Folic Acid Antagonists; Heterozygote; Humans; Mice; Models, Molecular; Molecular Conformation; Muscular Atrophy, Spinal; Nerve Tissue Proteins; Permeability; Piperidines; Promoter Regions, Genetic; Quinazolines; RNA-Binding Proteins; SMN Complex Proteins; Spinal Muscular Atrophies of Childhood; Stereoisomerism; Structure-Activity Relationship; Survival of Motor Neuron 1 Protein; Survival of Motor Neuron 2 Protein; Tetrahydrofolate Dehydrogenase | 2008 |